The latest price of Polatuzumab in 2025

Polatuzumab/Polatuzumab is an antibody-drug conjugate developed by Roche. It was approved by the US FDA in June 2019 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). The advent of this drug is considered to be one of the important breakthroughs in the treatment of hematological tumors. Its mechanism of action is through antibody recognition of the CD79b protein on the surface of B cells, and then releases the cytotoxin MMAE to directly kill cancer cells, thereby improving the patient's treatment outcome.

In terms of clinical application, velpotuzumab is usually combined with rituximab and bendamustine. This regimen is especially suitable for patients who have relapsed or are resistant after at least two lines of treatment. Overseas real-world data shows that the drug can improve the response rate and provide some patients with the opportunity for subsequent stem cell transplantation or CAR-T treatment. In China, as the drug has been officially approved and entered into medical insurance, its clinical application is rapidly expanding, especially in large hematological disease centers. Vepotolizumab has become an important choice for patients with relapsed and refractory lymphoma.

Regarding price, the specification of vepotuzumab currently available in China is 30mg/bottle, with a retail price of approximately RMB 10,000. Since it has been included in the national medical insurance catalog, the actual out-of-pocket proportion of patients will be significantly reduced, and the specific reimbursement amount needs to be determined according to local medical insurance policies. In the international market, the selling price in the United States and Europe is generally around US$3,900 per bottle, which is much higher than the domestic price level after conversion. This shows that my country's medical insurance negotiations play an important role in improving accessibility. Currently, there are no generic versions globally, so the market mainly relies on the supply of Roche’s original drugs.

In the future, with the expansion of indications and the accumulation of more real-world data, vepotuzumab may not only be limited to DLBCL, but may also show potential in other types of B-cell lymphomas.

Reference materials:https://www.drugs.com/polivy.html